Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13951541 | 0.89 | TSHR (0.47) | TSHRGAAKMT2AMEN1TP53 | |
| SCHEMBL13929251 | 0.86 | TSHR (0.45) | TSHRGAAKMT2AMEN1TP53 | |
| SCHEMBL13929304 | 0.85 | SIGMAR1 (0.46) | TSHRGAATP53SIGMAR1 | |
| SCHEMBL4220531 | 0.82 | SIGMAR1 (0.54) | TSHRSIGMAR1 | |
| SCHEMBL13929300 | 0.81 | SIGMAR1 (0.44) | TSHRKMT2AMEN1SIGMAR1 | |
| SCHEMBL13929298 | 0.81 | MAPT (0.44) | GAAKMT2AMEN1SIGMAR1MAPT | |
| SCHEMBL13929262 | 0.79 | SIGMAR1 (0.48) | TSHRKMT2AMEN1SIGMAR1 | |
| SCHEMBL13929291 | 0.77 | SIGMAR1 (0.46) | TSHRSIGMAR1 | |
| SCHEMBL13929263 | 0.77 | PKM (0.54) | TSHRSIGMAR1 | |
| SCHEMBL13929229 | 0.76 | OPRM1 (0.50) | TSHRKMT2AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | TSHR 636/4885GAA 4689/4885KMT2A 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.